These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 26373763)

  • 1. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.
    Ni T; Shang XS; Wang WT; Hu XX; Zeng MS; Rao SX
    Br J Radiol; 2018 Jul; 91(1088):20180017. PubMed ID: 29791202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.
    Kang Y; Lee JM; Kim SH; Han JK; Choi BI
    Radiology; 2012 Sep; 264(3):751-60. PubMed ID: 22798225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.
    Koh J; Chung YE; Nahm JH; Kim HY; Kim KS; Park YN; Kim MJ; Choi JY
    Eur Radiol; 2016 Feb; 26(2):407-16. PubMed ID: 26002136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
    Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
    J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
    Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
    Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.
    Park HJ; Jang KM; Kang TW; Song KD; Kim SH; Kim YK; Cha DI; Kim J; Goo J
    Eur Radiol; 2016 Sep; 26(9):3102-11. PubMed ID: 26634931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
    Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
    Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid-enhanced MR Imaging and Dynamic CT.
    Choi SH; Lee SS; Kim SY; Park SH; Park SH; Kim KM; Hong SM; Yu E; Lee MG
    Radiology; 2017 Mar; 282(3):771-781. PubMed ID: 27797675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma.
    Zhao F; Pang G; Li X; Yang S; Zhong H
    Sci Rep; 2021 Nov; 11(1):23163. PubMed ID: 34848818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
    Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.
    Haradome H; Unno T; Morisaka H; Toda Y; Kwee TC; Kondo H; Sano K; Ichikawa T; Kondo F; Sugitani M; Takayama T
    Eur Radiol; 2017 Nov; 27(11):4461-4471. PubMed ID: 28439650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Gu KW; Kim YK; Min JH; Ha SY; Jeong WK
    Abdom Radiol (NY); 2017 May; 42(5):1424-1433. PubMed ID: 28078380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI.
    Chang AI; Kim YK; Min JH; Lee J; Kim H; Lee SJ
    Abdom Radiol (NY); 2019 Apr; 44(4):1395-1406. PubMed ID: 30515535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
    Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
    Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
    Kim SS; Kim SH; Song KD; Choi SY; Heo NH
    J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.
    Phongkitkarun S; Limsamutpetch K; Tannaphai P; Jatchavala J
    World J Gastroenterol; 2013 Dec; 19(45):8357-65. PubMed ID: 24363528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in Cirrhotic Livers May Share Similar Enhancement Patterns at Multiphase Dynamic MR Imaging.
    Huang B; Wu L; Lu XY; Xu F; Liu CF; Shen WF; Jia NY; Cheng HY; Yang YF; Shen F
    Radiology; 2016 Oct; 281(1):150-7. PubMed ID: 27077381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.